Roxadustat

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Roxadustat
Roxadustat structure.png
Clinical data
SynonymsFG-4592
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.245.356 Edit this at Wikidata
Chemical and physical data
FormulaC19H16N2O5
Molar mass352.346 g·mol−1
3D model (JSmol)

Roxadustat (INN, also known as FG-4592, ASP1517 and AZD9941) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia secondary to chronic kidney disease.[1][2] Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs, as it has already been detected being used illicitly by athletes despite not having yet been approved for medical use.[3][4][5] Roxadustat received its first global approval in China on 17 December 2018 for the treatment of anaemia caused by CKD in patients who are dialysis-dependent.[6] Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth[7] and also is considered to cause pulmonary hypertension.[8]

See also[edit]

References[edit]

  1. ^ Provenzano, R.; Besarab, A.; Sun, C. H.; Diamond, S. A.; Durham, J. H.; Cangiano, J. L.; Aiello, J. R.; Novak, J. E.; Lee, T.; Leong, R.; Roberts, B. K.; Saikali, K. G.; Hemmerich, S.; Szczech, L. A.; Yu, K. H.; Neff, T. B. (2016). "Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD". Clinical Journal of the American Society of Nephrology. 11 (6): 982–91. doi:10.2215/CJN.06890615. PMC 4891748. PMID 27094610.
  2. ^ Becker, K.; Saad, M. (2017). "A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat". Advances in Therapy. 34 (4): 848–853. doi:10.1007/s12325-017-0508-9. PMID 28290095.
  3. ^ Beuck, S.; Schänzer, W.; Thevis, M. (2012). "Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis". Drug Testing and Analysis. 4 (11): 830–45. doi:10.1002/dta.390. PMID 22362605.
  4. ^ Buisson, C.; Marchand, A.; Bailloux, I.; Lahaussois, A.; Martin, L.; Molina, A. (2016). "Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case". Journal of Pharmaceutical and Biomedical Analysis. 121: 181–187. doi:10.1016/j.jpba.2016.01.029. PMID 26808067.
  5. ^ Eichner, D.; Van Wagoner, R. M.; Brenner, M.; Chou, J.; Leigh, S.; Wright, L. R.; Flippin, L. A.; Martinelli, M.; Krug, O.; Schänzer, W.; Thevis, M. (2017). "Lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls". Drug Testing and Analysis. 9 (11–12): 1768–1778. doi:10.1002/dta.2202. PMID 28378453.
  6. ^ Dhillon S. Roxadustat: First Global Approval.Drugs (2019) 79:563–572 https://doi.org/10.1007/s40265-019-01077-1
  7. ^ Zhou, M.; Hou, J.; Li, Y.; Mou, S.; Wang, Z.; Horch, R. E.; Sun, J.; Yuan, Q. (2019). "The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model". Sci. Rep. 9 (1): 6035. doi:10.1038/s41598-019-41924-5. PMC 6465281. PMID 30988335.
  8. ^ Cygulska, K.; Wejner-Mik, P.; Plewka, M.; Figiel, Ł.; Chrzanowski, Ł.; Kasprzak, J. D. (2019). "Roxadustat - another drug that causes pulmonary hypertension? - Report of first human case". Pol. Arch. Intern. Med. 129 (5): 344–345. doi:10.20452/pamw.4445. PMID 30758318.